Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryLinks, Skadden and A&O scoop roles on $9.2bn ice cream deal as Magnum splits from UnileverRevolving Doors: A&O Shearman builds in Riyadh as Kirkland, Paul Hastings, and more make flurry of City hiresThirty firms win roles in revamped £820m government legal panel – with three new appointmentsTaylor Wessing UK in transatlantic merger talks with Winston & StrawnMeal Deal Maker: LB lunches with top City partners – Ropes & Gray’s Libby ToddGoodwin boosts City private equity with Paul Hastings trioDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture